STOCK TITAN

NanoVibronix, Inc. - NAOV STOCK NEWS

Welcome to our dedicated page for NanoVibronix news (Ticker: NAOV), a resource for investors and traders seeking the latest updates and insights on NanoVibronix stock.

NanoVibronix, Inc. (NASDAQ: NAOV) is a forward-thinking medical device company specializing in the development and commercialization of innovative products that leverage its proprietary low-intensity acoustic technology. Located in Elmsford, NY, with a subsidiary, NanoVibronix Ltd., based in Nesher, Israel, the company aims to revolutionize the medical field with cost-effective therapeutic ultrasound applications.

NanoVibronix's groundbreaking technology enables the creation of miniature transducers that transmit low-frequency, low-intensity ultrasound through flexible material surfaces. This unique feature is integral to a range of products designed for various medical applications, particularly those requiring noninvasive methods.

The company's flagship products include:

  • PainShield®: A patch-based device carrying FDA clearance, designed for pain management through the delivery of therapeutic ultrasound.
  • UroShield®: A device aimed at preventing biofilm formation and reducing urinary tract infections associated with catheter use.
  • WoundShield®: A device that promotes wound healing by transmitting low-frequency ultrasound waves to stimulate tissue regeneration.

NanoVibronix's products are designed for home use, enabling patients to receive therapy without the need for medical professionals. This approach not only enhances patient convenience but also reduces healthcare costs.

In addition to its direct-to-patient sales, NanoVibronix partners with distributors to expand its market reach. The company's recent achievements include securing FDA clearance for PainShield® and forming strategic partnerships to enhance product distribution.

Overall, NanoVibronix, Inc. stands out for its innovative approach to medical device technology, focusing on noninvasive solutions for pain management, biofilm prevention, and wound healing, making significant strides in improving patient outcomes.

Rhea-AI Summary

NanoVibronix (NASDAQ: NAOV) has signed a non-binding term sheet for a license and supply agreement with APOGEPHA Arzneimittel GmbH, a German pharmaceutical company specializing in urology products. The agreement aims to distribute UroShield throughout Europe. UroShield is an ultrasound-based device designed to prevent bacterial colonization and biofilm on indwelling urinary catheters, potentially reducing catheter-associated urinary tract infections (CAUTI) and associated pain.

Brian Murphy, CEO of NanoVibronix, expressed enthusiasm about partnering with APOGEPHA, citing their leadership in urology and large sales and marketing team as key factors for accelerating UroShield sales in Germany. Dr. Dirk Pamperin, Chairman of APOGEPHA's Management Board, stated their commitment to offering high-quality urological products and their confidence in UroShield's ability to support patients with long-term catheters.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.87%
Tags
none
-
Rhea-AI Summary

NanoVibronix, Inc. (NASDAQ: NAOV) has signed a letter of intent with Medici Medical , a leading distributor of medical products in Israel, to explore distribution opportunities for its UroShield device in the Israeli healthcare market. This potential partnership aligns with NanoVibronix's strategy to expand distribution and accelerate market adoption of UroShield through established channels.

Brian Murphy, CEO of NanoVibronix, emphasized the importance of partnering with leading distributors to drive market adoption. Medici's CEO, Nufar Cohen, expressed interest in UroShield's reported benefits and plans to evaluate it further through market research. Medici specializes in importing, marketing, and distributing disposable medical devices and has established partnerships with international pharmaceutical companies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.88%
Tags
none
-
Rhea-AI Summary

NanoVibronix (NASDAQ: NAOV) reported significant growth in Q2 2024, with revenue reaching $817,000, over 2.5 times higher than Q2 2023. The company reduced its loss from operations by more than 30% to approximately ($674,000). Key highlights include:

1. Increased revenues from Veterans' Health System and Workers' Compensation markets
2. Strong balance sheet with $2.2 million cash and $2.4 million inventory
3. Progress in domestic sales channels, including VA facilities and DME distributors
4. International expansion in Australia, New Zealand, and the UK
5. Ongoing product development and research initiatives

The company remains focused on expanding distribution channels, nurturing relationships with accounts, and engaging consumers to drive profitable growth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.68%
Tags
none
Rhea-AI Summary

NanoVibronix (Nasdaq: NAOV) announced the start of the pilot phase for the UroShield clinical trial at the University of Michigan. This phase is the initial part of a broader study, following a Research Agreement signed on November 28, 2023. The trial aims to evaluate UroShield's efficacy in reducing urinary tract infections, catheter blockage, and pain, thereby enhancing patient quality of life. The pilot phase involves up to 30 patients, while the full study will involve approximately 300 patients, primarily from nursing homes. The goal is to gather data that will support an application for permanent FDA clearance or approval.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.67%
Tags
-
Rhea-AI Summary

NanoVibronix (NASDAQ: NAOV) issued an update on its business developments and financial performance for Q1 2024. The company reported record first-quarter revenues of $921,000, but also a loss from operations of $568,000. Cash reserves stand at $2.7 million with $2.6 million in inventory. Domestic sales, particularly within the Veterans Affairs (VA) and worker’s compensation markets, are seeing growth, aided by a new General Services Administration (GSA) grant effective May 1, 2024. Internationally, the company has made strides in the UK, Australia, and New Zealand. A significant research study on UroShield by the University of Michigan is underway, potentially bolstering FDA approval efforts. The company is also focused on improving existing products and exploring new opportunities. Key goals include expanding distribution channels and achieving broader market coverage.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.54%
Tags
none
-
Rhea-AI Summary

NanoVibronix (NASDAQ: NAOV) announced a distribution agreement with CB Medical, a VA-certified and Service-Disabled Veteran-Owned Small Business, for the sale and distribution of UroShield. UroShield, an ultrasound-based device, helps prevent bacterial colonization on urinary catheters, reduces catheter-associated urinary tract infections (CAUTI), and alleviates pain and discomfort. The multi-year agreement allows CB Medical to sell UroShield throughout the VA system in the U.S. Brian Murphy, CEO of NanoVibronix, highlighted the opportunity to expand UroShield's distribution and benefit veterans. Shawn Pinkston, CEO of CB Medical, emphasized the importance of offering effective solutions to veterans, especially those with spinal injuries who use indwelling catheters and are at high risk of infection.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.69%
Tags
none
Rhea-AI Summary

NanoVibronix, Inc. announced that its PainShield product will be included in the U.S. Department of Veteran Affairs’ Federal Supply Schedule (FSS) effective May 1, 2024. The five-year contract awarded to distribution partner Delta Medical, will provide a significant opportunity for NanoVibronix to expand the placement of PainShield devices within the VA healthcare network, serving nine million enrolled veterans annually. The contract aims to address the growing need for non-pharmacological pain management solutions, positioning PainShield as a valuable therapeutic option.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.12%
Tags
none
-
Rhea-AI Summary
NanoVibronix, Inc. (Nasdaq: NAOV) will be presenting at the Planet MicroCap Showcase: VEGAS 2024 on May 1, 2024. The CEO, Brian Murphy, will host the presentation. Investors can access the live webcast and book 1x1 meetings at the conference venue.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.6%
Tags
conferences
-
Rhea-AI Summary
NanoVibronix, Inc. (NAOV) reported record revenues of $1.2 million in Q4 2023, alongside a loss of $702,000. The company focuses on developing and commercializing therapeutic devices like UroShield, PainShield, and WoundShield. Despite challenges in obtaining full approval for PainShield from CMS, NanoVibronix is seeing growth in domestic and international markets. The company is also conducting a RCT study with the University of Michigan to evaluate the efficacy of UroShield.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.87%
Tags
none
Rhea-AI Summary
NanoVibronix, Inc. (NAOV) partners with Veranex, Inc. to enhance UroShield and PainShield products, aiming to add therapeutic functionality and cut costs. The collaboration focuses on research and development services to innovate the next generation of devices, ensuring improved quality and reduced expenses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.43%
Tags
none

FAQ

What is the current stock price of NanoVibronix (NAOV)?

The current stock price of NanoVibronix (NAOV) is $0.634 as of November 8, 2024.

What is the market cap of NanoVibronix (NAOV)?

The market cap of NanoVibronix (NAOV) is approximately 2.4M.

What does NanoVibronix, Inc. specialize in?

NanoVibronix, Inc. specializes in creating medical devices that utilize low-intensity acoustic technology for pain management, biofilm prevention, and wound healing.

Where is NanoVibronix, Inc. located?

NanoVibronix, Inc. is located in Elmsford, NY, with a subsidiary in Nesher, Israel.

What are the primary products of NanoVibronix, Inc.?

The primary products are PainShield®, UroShield®, and WoundShield®, all of which use low-frequency, low-intensity ultrasound technology.

Is PainShield® FDA cleared?

Yes, the PainShield® device has received FDA clearance for pain management.

How do NanoVibronix's products work?

NanoVibronix's products use small, disposable transducers to transmit low-frequency, low-intensity ultrasound waves that help with tissue repair, pain reduction, and biofilm prevention.

Can NanoVibronix's devices be used at home?

Yes, NanoVibronix's devices are designed for home use, allowing patients to receive therapy without the aid of medical professionals.

Does NanoVibronix sell its products directly to patients?

Yes, the company sells its products directly to patients and also through distributor agreements.

What is the purpose of UroShield®?

UroShield® is designed to prevent biofilm formation on urinary catheters and reduce urinary tract infections.

What is the goal of WoundShield®?

WoundShield® aims to promote wound healing by transmitting low-frequency ultrasound waves to stimulate tissue regeneration.

What recent achievements has NanoVibronix made?

Recent achievements include FDA clearance for PainShield® and forming strategic partnerships to enhance product distribution.

NanoVibronix, Inc.

Nasdaq:NAOV

NAOV Rankings

NAOV Stock Data

2.38M
3.75M
0.42%
8.38%
18.5%
Medical Devices
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Link
United States of America
ELMSFORD